Evidence map›Paper›PMID 42666037›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

AL398, A Novel NSUN6 Inhibitor, Attenuates Epithelial-Mesenchymal Transition and Metastasis in Endometrial Cancer by Abrogating m5C-Dependent Stabilization of Snail mRNA.

Xiangzhuan Zhao, Linlin Yang, Huanxiang Chen, Chenfeng Guo, Hongshen Lu, Ying Zhu, Xuanzhi Wang, Yang Li, Ruike Zhang, Zichong Huang and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Xiangzhuan Zhao *Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Linlin Yang *Department of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Huanxiang ChenDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Chenfeng GuoSchool of Pharmacy, Zhengzhou University, Zhengzhou, Henan, China.
Hongshen LuDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ying ZhuDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Xuanzhi WangDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yang LiDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ruike ZhangDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zichong HuangDepartment of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Yifang ChenDepartment of Pharmacology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China.
Keyu JinDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Zeduo XuDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Lingxiu MengDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Longfeng ZhangDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yuanyuan HanDepartment of Pathology, The Third Provincial Hospital of Henan, Zhengzhou, Henan, China.
Yicong YanDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID https://orcid.org/0009-0004-2438-7235
Qiaozhen KangSchool of Life Science, Zhengzhou University, Zhengzhou, Henan, China.
Junhu WanDepartment of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.ORCID https://orcid.org/0009-0008-3869-7153
Hongyang LiuDepartment of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.

Funding

Henan Clinical Medical Scientist Program HNCMS202514Henan Province Science and Technology Research Project 262102310052Joint Fund of Henan Province Science and Technology R&D Program 235200810039Joint Fund of Henan Province Science and Technology R&D Program 235200810085Medical Science and Technology Provincial and Ministerial Co-construction Project of Henan Province SBGJ202403034National Natural Science Foundation of China 31900895National Natural Science Foundation of China 82172351National Natural Science Foundation of China 82173018National Natural Science Foundation of China 82370113National Natural Science Foundation of China 82607625Natural Science Foundation of Henan Province 232300421054Natural Science Foundation of Henan Province 262300421153Zhengzhou University Graduate Education Research Project YJSJY2025165Zhengzhou University Graduate Education Research Project YJSJY2025182
6 · The paper itself

Abstract

Endometrial cancer (EC) constitutes a leading gynecologic malignancy for which advanced or metastatic disease presents limited therapeutic options. While RNA modifications are acknowledged as key regulatory elements in cancer, the role of 5-methylcytosine (m

Indexed as

EMTendometrial cancerm5C methylationNSUN6Snail

Identifiers

PMID42666037
PMCPMC13525354

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.